Bio-Rad Laboratories (BIO) 10-Q 1 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 23, 2019
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,836,205
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,098,637

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ASSETS:
Cash and cash equivalents	$ 561,071	$ 431,526
Short-term investments	418,177	413,270
Restricted investments	5,560	5,560
Accounts receivable, net	356,025	392,443
Inventories:
Raw materials	112,432	108,008
Work in process	141,268	145,051
Finished goods	334,287	330,756
Total inventories	587,987	583,815
Prepaid expenses	109,584	187,249
Other current assets	9,228	9,615
Total current assets	2,047,632	2,023,478
Property, plant and equipment	1,347,364	1,326,829
Less: accumulated depreciation and amortization	(851,488)	(818,139)
Property, plant and equipment, net	495,876	508,690
Operating lease right-of-use assets	217,516	0
Goodwill, net	264,084	219,770
Purchased intangibles, net	146,965	133,123
Other investments	3,931,715	2,655,709
Other assets	73,328	70,298
Total assets	7,177,116	5,611,068
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable, accrued payroll and employee benefits	249,835	265,960
Current maturities of long-term debt and notes payable	1,769	493
Income and other taxes payable	35,252	56,188
Current operating lease liabilities	33,694	0
Other current liabilities	113,490	128,154
Total current liabilities	434,040	450,795
Long-term debt, net of current maturities	437,808	438,937
Deferred income taxes	838,001	553,239
Operating lease liabilities	192,600	0
Other long-term liabilities	143,475	147,766
Total liabilities	2,045,924	1,590,737
Stockholders' equity:
Additional paid-in capital	396,432	394,342
Retained earnings	4,917,313	3,722,073
Accumulated other comprehensive loss	(152,113)	(46,958)
Total stockholders' equity	5,131,192	4,020,331
Total liabilities and stockholders' equity	7,177,116	5,611,068
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	(30,443)	(49,040)
Treasury Class B [Member]
Stockholders' equity:
Treasury stock	$ 0	$ (89)

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts receivable, less allowance for doubtful accounts	$ 23,147	$ 26,713
Common Class A [Member]
Common Stock, Shares, Issued	24,942,773	24,884,265
Common Stock, Shares, Outstanding	24,834,725	24,704,772
Common Class B [Member]
Common Stock, Shares, Issued	5,100,137	5,096,421
Common Stock, Shares, Outstanding	5,100,137	5,095,504
Treasury Class A [Member]
Treasury Stock, Shares	108,048	179,493
Treasury Class B [Member]
Treasury Stock, Shares	0	917

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net sales	$ 560,633	$ 545,138	$ 1,687,231	$ 1,672,568
Cost of goods sold	253,607	258,422	760,674	781,982
Gross profit	307,026	286,716	926,557	890,586
Selling, general and administrative expense	201,622	201,196	610,460	620,751
Research and Development Expense	47,944	49,245	145,641	146,122
Segment profit (loss)	57,460	36,275	170,456	123,713
Interest expense	5,525	6,064	17,352	17,823
Foreign exchange (gains) losses, net	898	672	3,411	1,911
Marketable Securities, Unrealized (Gain) Loss	390,620	(318,007)	(1,384,999)	(1,420,339)
Nonoperating Income (Expense)	4,367	2,585	26,959	29,588
Income before income taxes	(335,216)	350,131	1,561,651	1,553,906
(Provision) benefit for income taxes	76,400	(80,805)	(356,462)	(359,763)
Net income attributable to Bio-Rad	$ (258,816)	$ 269,326	$ 1,205,189	$ 1,194,143
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ (8.68)	$ 9.02	$ 40.42	$ 40.04
Weighted average common shares - basic	29,831	29,863	29,815	29,822
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ (8.68)	$ 8.89	$ 39.97	$ 39.50
Weighted average common shares - diluted	29,831	30,292	30,149	30,234

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net Income (Loss) Attributable to Parent	$ (258,816)	$ 269,326	$ 1,205,189	$ 1,194,143
Foreign currency translation adjustments	(103,332)	(13,556)	(109,888)	(91,128)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	359	105	501	1,281
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	433	(138)	4,232	(1,989)
Total other comprehensive income (loss) net of tax	(102,540)	(13,589)	(105,155)	(91,836)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (361,356)	$ 255,737	$ 1,100,034	$ 1,102,307

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Cash received from customers	$ 1,716,486	$ 1,715,960
Cash paid to suppliers and employees	(1,392,653)	(1,494,794)
Interest paid, net	(11,381)	(11,721)
Income tax payments, net	(42,634)	(57,840)
Investment proceeds and miscellaneous receipts, net	28,092	21,601
Proceeds from forward foreign exchange contracts, net	185	7,279
Net cash provided by operating activities	298,095	180,485
Cash flows from investing activities:
Capital expenditures	(76,934)	(75,951)
Proceeds from dispositions of property, plant and equipment	85	4,273
Proceeds from divestiture of a product line	0	6,964
(Payments for) proceeds from acquisitions, net of cash received	(75,811)	266
Recovery of (payments for) purchases of intangible assets	7,383	(3)
Payments for purchases of marketable securities and investments	(266,839)	(286,826)
Proceeds from sales of marketable securities and investments	83,315	60,488
Proceeds from maturities of marketable securities and investments	181,108	158,622
Net cash used in investing activities	(147,693)	(132,167)
Cash flows from financing activities:
Payments on long-term borrowings	(487)	(1,595)
Payments for credit agreement renewal fees	(486)	0
Payments of contingent consideration	(2,477)	(2,078)
Proceeds from Issuance of Common Stock	9,740	10,858
Tax payments from net share settlement	(8,096)	(8,862)
Proceeds from reissuances of treasury stock for share-based compensation, net	3,831	0
Payments for purchases of treasury stock	(20,000)	0
Net cash used in financing activities	(17,975)	(1,677)
Effect of foreign exchange rate changes on cash	(3,239)	3,965
Net increase in cash, cash equivalents, and restricted cash	129,188	50,606
Beginning Cash, Cash Equivalents, and Restricted Cash	434,164	384,983
Cash and cash equivalents	561,071	434,517
Restricted Cash, Current	100	102
Restricted Cash, Noncurrent	2,181	970
Ending Cash, Cash Equivalents, and Restricted Cash	$ 563,352	$ 435,589

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2017	$ 2,930,250	$ 3	$ 361,231	$ (217)	$ 1,830,439	$ 738,794
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	656,774				656,774
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	44,548					44,548
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	5,885		5,885
Proceeds from Issuance of Common Stock	3,872		3,872
Total Stockholders' Equity at Mar. 31, 2018	4,488,091	3	370,988	(217)	4,013,232	104,085
Total Stockholders' Equity at Dec. 31, 2017	2,930,250	3	361,231	(217)	1,830,439	738,794
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	1,194,143
Proceeds from Issuance of Common Stock	10,858
Total Stockholders' Equity at Sep. 30, 2018	4,900,481	3	382,393	(217)	4,550,601	(32,299)
Total Stockholders' Equity at Mar. 31, 2018	4,488,091	3	370,988	(217)	4,013,232	104,085
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	268,043				268,043
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(122,795)					(122,795)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,205		6,205
Proceeds from Issuance of Common Stock	(598)		(598)
Total Stockholders' Equity at Jun. 30, 2018	4,638,946	3	376,595	(217)	4,281,275	(18,710)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	269,326				269,326
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(13,589)					(13,589)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	7,076		7,076
Proceeds from Issuance of Common Stock	(1,278)		(1,278)
Total Stockholders' Equity at Sep. 30, 2018	4,900,481	3	382,393	(217)	4,550,601	(32,299)
Total Stockholders' Equity at Dec. 31, 2018	4,020,331	3	394,342	(49,129)	3,722,073	(46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	865,195				865,195
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(34,007)					(34,007)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,505		8,505
Treasury Stock Reissued at Lower than Repurchase Price	3,831			5,398	(1,567)
Total Stockholders' Equity at Mar. 31, 2019	4,863,855	3	402,847	(43,731)	4,585,701	(80,965)
Total Stockholders' Equity at Dec. 31, 2018	4,020,331	3	394,342	(49,129)	3,722,073	(46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	1,205,189
Proceeds from Issuance of Common Stock	9,740
Total Stockholders' Equity at Sep. 30, 2019	5,131,192	3	396,432	(30,443)	4,917,313	(152,113)
Total Stockholders' Equity at Mar. 31, 2019	4,863,855	3	402,847	(43,731)	4,585,701	(80,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	598,810				598,810
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	31,392					31,392
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	7,818		7,818
Proceeds from Issuance of Common Stock	(64)		(64)
Total Stockholders' Equity at Jun. 30, 2019	5,486,810	3	410,601	(58,732)	5,184,511	(49,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value, Acquired, Cost Method	(15,001)			(15,001)
Net Income (Loss) Attributable to Parent	(258,816)				(258,816)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(102,540)					(102,540)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	9,029		9,029
Treasury Stock Reissued at Lower than Repurchase Price	0		(24,906)	33,288	(8,382)
Proceeds from Issuance of Common Stock	1,708		1,708
Total Stockholders' Equity at Sep. 30, 2019	5,131,192	$ 3	$ 396,432	(30,443)	$ 4,917,313	$ (152,113)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value, Acquired, Cost Method	$ (4,999)			$ (4,999)

1. Organization, Consolidation

1. Organization, Consolidation and Presentation of Financial Statements	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2018 . We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Revenue Recognition On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed further below under the captions “Leases” and “Recent Accounting Pronouncements Adopted,” as well as in Note 14, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our condensed consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. As a result, our lease income is heavily variable in nature. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income​.​ Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three and nine months ended September 30, 2019 , and approximately 5% of total revenue for both the three and nine months ended September 30, 2018 , and is included as part of Net sales in our Condensed Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Europe $ 181.9 $ 182.7 $ 556.1 $ 579.5 Asia 120.7 110.3 354.3 341.7 United States 225.8 218.3 674.0 649.8 Other (primarily Canada and Latin America) 32.2 33.8 102.8 101.6 Total Net sales $ 560.6 $ 545.1 $ 1,687.2 $ 1,672.6 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.6 million at September 30, 2019 is primarily driven by $30.1 million , net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $21.8 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018 . We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): December 31, 2018 $ 10.1 Provision for warranty 7.3 Actual warranty costs (8.4 ) September 30, 2019 $ 9.0 Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Condensed Consolidated Balance Sheet as of September 30, 2019 . Finance leases are included in Property, plant and equipment, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our Condensed Consolidated Balance Sheet as of September 30, 2019 . ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements and Securities and Exchange Commission ("SEC") Rule Adopted In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of September 30, 2019 , we capitalized $2.4 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Condensed Consolidated Balance Sheet. In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities, see Note 14, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Condensed Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements to be Adopted In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans. In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

2. Acquisitions (Notes)

2. Acquisitions (Notes)	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITIONS In August 2019, we acquired all the issued and outstanding membership interests of a small U.S. manufacturer for approximately $60.0 million . Cash payments at closing, net of closing cash, were $59.7 million . The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. As of September 30, 2019 , the preliminary allocation of the payments were $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets acquired and liabilities assumed. We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations. In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million . Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments were $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

3. Fair Value Measurements

3. Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 76.6 $ — $ 76.6 Asset-backed securities — 0.1 — 0.1 U.S. government sponsored agencies — 3.2 — 3.2 Time deposits 23.6 10.0 — 33.6 Money market funds 62.9 — — 62.9 Total cash equivalents (a) 86.5 89.9 — 176.4 Restricted investment 5.6 — — 5.6 Equity securities (b) 3,950.5 — — 3,950.5 Available-for-sale investments: Corporate debt securities — 181.7 — 181.7 U.S. government sponsored agencies — 98.5 — 98.5 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 10.7 — 10.7 Asset-backed securities — 72.2 — 72.2 Total available-for-sale investments (c) — 370.9 — 370.9 Forward foreign exchange contracts (d) — 0.5 — 0.5 Total financial assets carried at fair value $ 4,042.6 $ 461.3 $ — $ 4,503.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.8 $ — $ 0.8 Contingent consideration (f) — — 5.3 5.3 Total financial liabilities carried at fair value $ — $ 0.8 $ 5.3 $ 6.1 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 77.8 $ — $ 77.8 Time deposits 22.7 10.0 — 32.7 Asset-backed securities — 0.3 — 0.3 Money market funds 36.9 — — 36.9 Total cash equivalents (a) 59.6 88.1 — 147.7 Restricted investment 5.6 — — 5.6 Equity securities (b) 2,672.9 — — 2,672.9 Available-for-sale investments: Corporate debt securities — 215.0 — 215.0 U.S. government sponsored agencies — 80.3 — 80.3 Foreign government obligations — 3.6 — 3.6 Municipal obligations — 11.0 — 11.0 Asset-backed securities — 63.3 — 63.3 Total available-for-sale investments (c) — 373.2 — 373.2 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 2,738.1 $ 461.9 $ — $ 3,200.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.7 $ — $ 0.7 Contingent consideration (f) — — 8.4 8.4 Total financial liabilities carried at fair value $ — $ 0.7 $ 8.4 $ 9.1 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 47.4 $ 40.2 Other investments 3,903.1 2,632.7 Total $ 3,950.5 $ 2,672.9 The year-to-date unrealized gains on our equity securities as of September 30, 2019 were $1,385.0 million and were primarily due to our investment in Sartorius AG and are recorded in our Condensed Consolidated Statements of Income. (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 370.8 $ 373.0 Other investments 0.1 0.2 Total $ 370.9 $ 373.2 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Other current liabilities $ 3.7 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 5.3 $ 8.4 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020 . The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2019 , we paid $1.4 million and $1.1 million , respectively, per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by net $12.9 million . The contingent consideration was accrued at its estimated fair value of $5.3 million as of September 30, 2019 . The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2018 $ 8.4 Payment of sales milestone (2.5 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (0.6 ) September 30, 2019 $ 5.3 The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of September 30, 2019 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.4 % Average cost of debt 3.9 % To estimate the fair value of Level 2 debt securities as of September 30, 2019 , our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. For all commercial paper as of September 30, 2019 , our primary pricing provider uses its leading pricing source in the hierarchy to determine pricing. Our pricing provider performs daily reasonableness testing of the Reuters prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Reuters prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved. Available-for-sale investments consist of the following (in millions): September 30, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 180.3 $ 1.5 $ (0.1 ) $ 181.7 Municipal obligations 10.6 0.1 — 10.7 Asset-backed securities 72.0 0.2 (0.1 ) 72.1 U.S. government sponsored agencies 97.6 1.0 (0.1 ) 98.5 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 368.3 2.8 (0.3 ) 370.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 368.4 $ 2.8 $ (0.3 ) $ 370.9 The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2019 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 139.9 $ 140.0 Mature in one to five years 168.3 169.4 Mature in more than five years 60.2 61.5 Total $ 368.4 $ 370.9 Available-for-sale investments consist of the following (in millions): December 31, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 216.2 $ 0.1 $ (1.3 ) $ 215.0 Municipal obligations 11.1 — (0.1 ) 11.0 Asset-backed securities 63.5 — (0.4 ) 63.1 U.S. government sponsored agencies 80.9 0.2 (0.8 ) 80.3 Foreign government obligations 3.6 — — 3.6 375.3 0.3 (2.6 ) 373.0 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 375.5 $ 0.3 $ (2.6 ) $ 373.2 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): September 30, 2019 December 31, 2018 Fair value of investments in a loss position 12 months or more $ 27.3 $ 117.9 Fair value of investments in a loss position less than 12 months $ 90.3 $ 193.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 1.8 Gross unrealized losses for investments in a loss position less than 12 months $ 0.2 $ 0.8 The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at September 30, 2019 or at December 31, 2018 . As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2019 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2019 Contracts maturing in October through December 2019 to sell foreign currency: Notional value $ 37.6 Unrealized gain or loss $ — Contracts maturing in October through December 2019 to purchase foreign currency: Notional value $ 232.5 Unrealized loss $ 0.2 The estimated fair value of our long-term debt, excluding all leases and current maturities, that is not recognized at fair value in the Condensed Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our long-term debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): September 30, 2019 December 31, 2018 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total long-term debt, excluding leases and current maturities $ 424.2 $ 435.1 2 $ 423.7 $ 435.8 2 Included in Other Investments in the Condensed Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $3.6 million and $0.6 million as of September 30, 2019 and December 31, 2018

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2018: Goodwill $ 234.5 $ 320.5 $ 555.0 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net 192.7 27.1 219.8 Acquisitions 15.6 28.7 44.3 Balances as of September 30, 2019: Goodwill 250.1 349.2 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 In conjunction with the purchase of all the issued and outstanding membership interest of a small U.S. manufacturer in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog. In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset. Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): September 30, 2019 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-10 $ 101.4 $ (70.4 ) $ 31.0 Know how 1-6 186.0 (158.9 ) 27.1 Developed product technology 1-13 141.5 (90.1 ) 51.4 Licenses 6-10 75.7 (43.3 ) 32.4 Tradenames 2-10 6.4 (3.5 ) 2.9 Covenants not to compete 6 3.2 (1.3 ) 1.9 Other 1 0.1 — 0.1 Total definite-lived intangible assets 514.3 (367.5 ) 146.8 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 514.5 $ (367.5 ) $ 147.0 December 31, 2018 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-6 $ 88.7 $ (68.3 ) $ 20.4 Know how 1-7 190.6 (159.8 ) 30.8 Developed product technology 1-10 130.4 (86.6 ) 43.8 Licenses 7-11 76.3 (40.9 ) 35.4 Tradenames 2-6 3.9 (3.3 ) 0.6 Covenants not to compete 7 3.2 (1.1 ) 2.1 Total definite-lived intangible assets $ 493.1 $ (360.0 ) $ 133.1 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Amortization expense $ 6.0 $ 7.0 $ 17.1 $ 21.8

5. Supplemental Cash Flow Info

5. Supplemental Cash Flow Information (Notes)	9 Months Ended
	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2019 September 30, 2018 Net income $ 1,205.2 $ 1,194.1 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 99.8 103.6 Right-of-use asset amortization 31.1 — Share-based compensation 25.4 19.2 (Gains) losses on dispositions of securities (0.2 ) 1.0 Other-than-temporary impairment loss on investment 1.6 — Change in fair market value of equity securities (1,385.0 ) (1,420.3 ) Gain on divestiture of a product line — (5.1 ) Losses on dispositions of fixed assets 0.3 1.2 Gain on sale of land — (4.1 ) Changes in fair value of contingent consideration (0.6 ) (6.5 ) Payments for operating lease liabilities (27.6 ) — Decrease in accounts receivable 30.4 72.2 Increase in inventories (14.5 ) (26.3 ) Decrease (increase) in other current assets 47.9 (8.9 ) Decrease in accounts payable and other current liabilities (24.6 ) (43.1 ) Decrease in income taxes payable (2.8 ) (22.1 ) Increase in deferred income taxes 310.9 316.7 Increase in other long term liabilities 5.5 5.4 Other (4.7 ) 3.5 Net cash provided by operating activities $ 298.1 $ 180.5 Non-cash investing activities: Purchased property, plant and equipment $ 4.5 $ 5.7 Purchased marketable securities and investments $ 2.8 $ 1.2

6. Long-Term Debt

6. Long-Term Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-term Debt	LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): September 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.8 ) (1.3 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.2 423.7 Capital leases and other debt — 15.7 Finance leases and other debt 15.4 — 439.6 439.4 Less current maturities (1.8 ) (0.5 ) Long-term debt $ 437.8 $ 438.9 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of September 30, 2019 . There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In April 2019, Bio-Rad entered into a $200 million unsecured Credit Agreement. Borrowings under the 2019 Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement as of September 30, 2019 , however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of September 30, 2019 . The 2019 Credit Agreement matures in April 2024. If we had borrowed against our 2019 Credit Agreement, the borrowing rate would have been 3.225% at September 30, 2019 , which is based on the 3-month LIBOR. The 2019 Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of September 30, 2019 .

7. Accumulated Other Comprehen

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (109.9 ) 0.1 5.1 (104.7 ) Amounts reclassified from Accumulated other comprehensive income — 0.6 (0.3 ) 0.3 Income tax effects — (0.2 ) (0.6 ) (0.8 ) Other comprehensive (loss) income, net of income taxes (109.9 ) 0.5 4.2 (105.2 ) Balances as of September 30, 2019: $ (145.4 ) $ (14.3 ) $ 7.5 $ (152.2 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2018: $ 77.4 $ (22.3 ) $ 4.5 $ 59.6 Other comprehensive (loss) income, before reclassifications (91.2 ) 0.5 (2.3 ) (93.0 ) Amounts reclassified from Accumulated other comprehensive income — 1.2 0.3 1.5 Income tax effects — (0.4 ) — (0.4 ) Other comprehensive (loss) income, net of income taxes (91.2 ) 1.3 (2.0 ) (91.9 ) Balances as of September 30, 2018: $ (13.8 ) $ (21.0 ) $ 2.5 $ (32.3 ) The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended Nine Months Ended September 30, September 30, Components of Comprehensive income 2019 2018 2019 2018 Location Amortization of foreign other post-employment benefit items $ (0.2 ) $ (0.4 ) $ (0.6 ) $ (1.2 ) Other (income) expense, net Net holding gains (losses) on equity securities and available-for-sale investments $ 0.2 $ (0.1 ) $ 0.3 $ (0.3 ) Other (income) expense, net Reclassification adjustments are calculated using the specific identification method.

8. Earnings Per Share

8. Earnings Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	. EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings (loss) per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive. For the three months ended September 30, 2019, net loss per basic share was the same as net loss per diluted share because all potentially dilutive shares were anti-dilutive due to the net loss for the period. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Basic weighted average shares outstanding 29,831 29,863 29,815 29,822 Effect of potentially dilutive stock options and restricted stock awards — 429 334 412 Diluted weighted average common shares 29,831 30,292 30,149 30,234 Anti-dilutive shares 95 64 56 35

9. Other Income and Expenses

9. Other Income and Expenses	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Interest and investment income $ (4.1 ) $ (2.6 ) $ (27.4 ) $ (20.9 ) Net realized (gain) loss on investments (0.2 ) 0.1 (0.2 ) 0.3 Other-than-temporary impairment loss on investment — — 1.6 — Gain on sale of land — — — (4.1 ) Gain on divestiture of product line — — — (5.1 ) Other (income) expense (0.1 ) (0.1 ) (1.0 ) 0.2 Other (income) expense, net $ (4.4 ) $ (2.6 ) $ (27.0 ) $ (29.6 ) An other-than-temporary impairment loss on investment was recorded in light of the investee's financial condition in the first quarter of 2019.

10. Income Taxes

10. Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	. INCOME TAXES Our effective income tax rate was 23% for both the three and nine months ended September 30, 2019 and 2018 . The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of September 30, 2019 , and have maintained a valuation allowance on such deferred tax assets. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. As of September 30, 2019 , based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $2.1 million

11. Segment Information Segmen

11. Segment Information Segment Reporting	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Information regarding industry segments for the three months ended September 30, 2019 and 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 215.7 $ 341.8 $ 3.1 2018 $ 206.6 $ 334.0 $ 4.5 Segment net profit (loss) 2019 $ 11.6 $ 43.8 $ (0.4 ) 2018 $ 10.2 $ 22.4 $ 0.1 Information regarding industry segments for the nine months ended September 30, 2019 and 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 643.9 $ 1,032.9 $ 10.4 2018 $ 622.2 $ 1,038.8 $ 11.6 Segment net profit (loss) 2019 $ 45.9 $ 117.1 $ (1.1 ) 2018 $ 25.7 $ 86.8 $ 0.1 Information regarding industry segments at September 30, 2019 , and December 31, 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment assets September 30, 2019 $ 500.0 $ 1,085.6 $ 7.8 December 31, 2018 $ 450.2 $ 949.0 $ 5.9 Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended September 30, 2019 compared to the same period in 2018 , our Life Science segment had increased sales, partially offset by increased cost of goods sold and selling, general and administrative expense, while our Clinical Diagnostics segment had increased sales, decreased cost of goods sold, along with decreased selling, general and administrative expense. For the nine months ended September 30, 2019 compared to the same period in 2018 , our Life Science segment had increased sales and decreased cost of goods sold, partially offset by increased research and development expense, while our Clinical Diagnostics segment had decreased sales, offset by decreased cost of goods sold, selling, general and administrative and research and development expenses. Segment assets at September 30, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 14, "Leases"). The following reconciles total segment profit to consolidated (loss) income before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Total segment profit $ 55.0 $ 32.7 $ 161.9 $ 112.6 Foreign currency exchange losses, net (0.9 ) (0.7 ) (3.4 ) (1.9 ) Net corporate operating, interest and other expense not allocated to segments (3.1 ) (2.5 ) (8.8 ) (6.7 ) Change in fair market value of equity securities (390.6 ) 318.0 1,385.0 1,420.3 Other income (expense), net 4.4 2.6 27.0 29.6 Consolidated (loss) income before income taxes $ (335.2 ) $ 350.1 $ 1,561.7 $ 1,553.9 The following reconciles total segment assets to consolidated total assets (in millions): September 30, 2019 December 31, 2018 Total segment assets $ 1,593.4 $ 1,405.1 Cash and other current assets 1,103.6 1,047.2 Property, plant and equipment, net, excluding segment specific gross machinery and equipment 64.0 79.9 Goodwill, net 264.1 219.8 Other long-term assets 4,152.0 2,859.1 Total assets $ 7,177.1 $ 5,611.1

12. Legal Proceedings

12. Legal Proceedings	9 Months Ended
	Sep. 30, 2019
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	12. LEGAL PROCEEDINGS On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million , plus prejudgment interest of $141,608 , post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24, 2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on the third quarter 2019 results of operations and is now closed. We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

13. Restructuring Costs (Notes)

13. Restructuring Costs (Notes)	9 Months Ended
	Sep. 30, 2019
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded less than $0.1 million and $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and nine months ended September 30, 2019 , respectively. The amounts recorded were reflected in Cost of goods sold of $(0.1) million in the Condensed Consolidated Statements of Income for the nine months ended September 30, 2019 . From May 2016 to September 30, 2019 , total expenses were $12.7 million . The liability of $0.7 million as of September 30, 2019 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets, and is expected to be paid or adjusted by the end of 2019. Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded less than $0.1 million and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019 , respectively. From December 2017 to September 30, 2019 , total expenses were $21.4 million . In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded no adjustments and $(0.3) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019 , respectively. From June 2018 to September 30, 2019 , total expenses were $1.4 million . In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded no adjustments and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019 , respectively. From December 2018 to September 30, 2019 , total expenses were $4.1 million . Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of zero and $(0.2) million , and in Research and development expense of zero and $(0.1) million in the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2019 , respectively. The liability of $3.5 million as of September 30, 2019 consisted of $1.4 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.9 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2018: $ 11.5 Adjustment to expense (0.3 ) Cash payments (7.4 ) Foreign currency translation gains (0.3 ) Balances as of September 30, 2019: $ 3.5

14. Leases (Notes)

14. Leases (Notes)	9 Months Ended
	Sep. 30, 2019
14. Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	14. LEASES We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 20 years, which includes our determination to exercise renewal options. The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2019 Operating lease cost $ 14.2 $ 38.7 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.5 Interest on lease liabilities 0.2 0.7 Total finance lease cost $ 0.3 $ 1.2 Sublease income $ 0.7 $ 2.2 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original right-of-use asset amortization, the impact of remeasurements, modifications, impairments and abandonments. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.6 $ 34.5 Operating cash flows from finance leases $ 0.2 $ 0.7 Financing cash flows from finance leases $ 0.1 $ 0.5 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 14.4 $ 20.2 Finance leases $ 0.1 $ 0.1 Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2019 Operating Leases Operating lease right-of-use assets $ 217.5 Current operating lease liabilities $ 33.7 Operating lease liabilities 192.6 Total operating lease liabilities $ 226.3 September 30, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 Less: accumulated depreciation and amortization (4.0 ) Property, plant and equipment, net $ 7.4 Current maturities of long-term debt and notes payable $ 0.5 Long-term debt, net of current maturities 11.2 Total finance lease liabilities $ 11.7 September 30, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 Finance leases - in years 18 Weighted Average Discount Rate Operating leases 4.3 % Finance leases 6.5 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2019 (excluding the nine months ended September 30, 2019) $ 11.1 $ 1.2 2020 41.0 1.3 2021 35.4 1.2 2022 27.9 1.1 2023 24.3 1.1 Thereafter 141.3 15.4 Total lease payments 281.0 21.3 Less imputed interest (54.7 ) (9.6 ) Total $ 226.3 $ 11.7 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over. Operating and Capital Lease Commitments Under ASC 840, Leases Annual future minimum lease payments at December 31, 2018 under operating leases were as follows: 2019 - $44.4 million ; 2020 - $37.8 million ; 2021 - $27.4 million ; 2022 - $19.7 million ; 2023 - $13.9 million ; and 2024 and beyond - $25.6 million . The total minimum rentals to be received in the future for the sublease as of December 31, 2018 were $17.8 million and ends in 2025. Maturities of our capital lease obligations at December 31, 2018 were as follows: 2019 - $0.5 million ; 2020 - $0.2 million ; 2021 - $0.5 million ; 2022 - $0.4 million ; 2023 - $0.4 million ; thereafter - $9.9 million .

1. Basis of Presentation and U

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Standard Product Warranty, Policy [Policy Text Block]	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): December 31, 2018 $ 10.1 Provision for warranty 7.3 Actual warranty costs (8.4 ) September 30, 2019 $ 9.0
Lessee, Leases [Policy Text Block]	Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Condensed Consolidated Balance Sheet as of September 30, 2019 . Finance leases are included in Property, plant and equipment, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our Condensed Consolidated Balance Sheet as of September 30, 2019 . ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements."
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements and Securities and Exchange Commission ("SEC") Rule Adopted In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of September 30, 2019 , we capitalized $2.4 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Condensed Consolidated Balance Sheet. In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities, see Note 14, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Condensed Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements to be Adopted In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans. In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed further below under the captions “Leases” and “Recent Accounting Pronouncements Adopted,” as well as in Note 14, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our condensed consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. As a result, our lease income is heavily variable in nature. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income​.​ Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three and nine months ended September 30, 2019 , and approximately 5% of total revenue for both the three and nine months ended September 30, 2018 , and is included as part of Net sales in our Condensed Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Europe $ 181.9 $ 182.7 $ 556.1 $ 579.5 Asia 120.7 110.3 354.3 341.7 United States 225.8 218.3 674.0 649.8 Other (primarily Canada and Latin America) 32.2 33.8 102.8 101.6 Total Net sales $ 560.6 $ 545.1 $ 1,687.2 $ 1,672.6 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.6 million at September 30, 2019 is primarily driven by $30.1 million , net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $21.8 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018 .

1. Basis of Presentation and_2

1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Europe $ 181.9 $ 182.7 $ 556.1 $ 579.5 Asia 120.7 110.3 354.3 341.7 United States 225.8 218.3 674.0 649.8 Other (primarily Canada and Latin America) 32.2 33.8 102.8 101.6 Total Net sales $ 560.6 $ 545.1 $ 1,687.2 $ 1,672.6
Schedule of Product Warranty Liability [Table Text Block]	Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): December 31, 2018 $ 10.1 Provision for warranty 7.3 Actual warranty costs (8.4 ) September 30, 2019 $ 9.0

3. Fair Value Measurements (Ta

3. Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): September 30, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 180.3 $ 1.5 $ (0.1 ) $ 181.7 Municipal obligations 10.6 0.1 — 10.7 Asset-backed securities 72.0 0.2 (0.1 ) 72.1 U.S. government sponsored agencies 97.6 1.0 (0.1 ) 98.5 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 368.3 2.8 (0.3 ) 370.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 368.4 $ 2.8 $ (0.3 ) $ 370.9
Schedule of financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 76.6 $ — $ 76.6 Asset-backed securities — 0.1 — 0.1 U.S. government sponsored agencies — 3.2 — 3.2 Time deposits 23.6 10.0 — 33.6 Money market funds 62.9 — — 62.9 Total cash equivalents (a) 86.5 89.9 — 176.4 Restricted investment 5.6 — — 5.6 Equity securities (b) 3,950.5 — — 3,950.5 Available-for-sale investments: Corporate debt securities — 181.7 — 181.7 U.S. government sponsored agencies — 98.5 — 98.5 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 10.7 — 10.7 Asset-backed securities — 72.2 — 72.2 Total available-for-sale investments (c) — 370.9 — 370.9 Forward foreign exchange contracts (d) — 0.5 — 0.5 Total financial assets carried at fair value $ 4,042.6 $ 461.3 $ — $ 4,503.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.8 $ — $ 0.8 Contingent consideration (f) — — 5.3 5.3 Total financial liabilities carried at fair value $ — $ 0.8 $ 5.3 $ 6.1 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 77.8 $ — $ 77.8 Time deposits 22.7 10.0 — 32.7 Asset-backed securities — 0.3 — 0.3 Money market funds 36.9 — — 36.9 Total cash equivalents (a) 59.6 88.1 — 147.7 Restricted investment 5.6 — — 5.6 Equity securities (b) 2,672.9 — — 2,672.9 Available-for-sale investments: Corporate debt securities — 215.0 — 215.0 U.S. government sponsored agencies — 80.3 — 80.3 Foreign government obligations — 3.6 — 3.6 Municipal obligations — 11.0 — 11.0 Asset-backed securities — 63.3 — 63.3 Total available-for-sale investments (c) — 373.2 — 373.2 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 2,738.1 $ 461.9 $ — $ 3,200.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.7 $ — $ 0.7 Contingent consideration (f) — — 8.4 8.4 Total financial liabilities carried at fair value $ — $ 0.7 $ 8.4 $ 9.1 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 47.4 $ 40.2 Other investments 3,903.1 2,632.7 Total $ 3,950.5 $ 2,672.9 The year-to-date unrealized gains on our equity securities as of September 30, 2019 were $1,385.0 million and were primarily due to our investment in Sartorius AG and are recorded in our Condensed Consolidated Statements of Income. (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 370.8 $ 373.0 Other investments 0.1 0.2 Total $ 370.9 $ 373.2 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Other current liabilities $ 3.7 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 5.3 $ 8.4
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2018 $ 8.4 Payment of sales milestone (2.5 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (0.6 ) September 30, 2019 $ 5.3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of September 30, 2019 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.4 % Average cost of debt 3.9 %
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): December 31, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 216.2 $ 0.1 $ (1.3 ) $ 215.0 Municipal obligations 11.1 — (0.1 ) 11.0 Asset-backed securities 63.5 — (0.4 ) 63.1 U.S. government sponsored agencies 80.9 0.2 (0.8 ) 80.3 Foreign government obligations 3.6 — — 3.6 375.3 0.3 (2.6 ) 373.0 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 375.5 $ 0.3 $ (2.6 ) $ 373.2
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): September 30, 2019 December 31, 2018 Fair value of investments in a loss position 12 months or more $ 27.3 $ 117.9 Fair value of investments in a loss position less than 12 months $ 90.3 $ 193.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 1.8 Gross unrealized losses for investments in a loss position less than 12 months $ 0.2 $ 0.8
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2019 Contracts maturing in October through December 2019 to sell foreign currency: Notional value $ 37.6 Unrealized gain or loss $ — Contracts maturing in October through December 2019 to purchase foreign currency: Notional value $ 232.5 Unrealized loss $ 0.2
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2019 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 139.9 $ 140.0 Mature in one to five years 168.3 169.4 Mature in more than five years 60.2 61.5 Total $ 368.4 $ 370.9
Estimated fair value of financial instruments	The estimated fair value of our long-term debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): September 30, 2019 December 31, 2018 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total long-term debt, excluding leases and current maturities $ 424.2 $ 435.1 2 $ 423.7 $ 435.8 2

4. Intangible Assets, Goodwi_2

4. Intangible Assets, Goodwill and Other (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2018: Goodwill $ 234.5 $ 320.5 $ 555.0 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net 192.7 27.1 219.8 Acquisitions 15.6 28.7 44.3 Balances as of September 30, 2019: Goodwill 250.1 349.2 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 In conjunction with the purchase of all the issued and outstanding membership interest of a small U.S. manufacturer in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog. In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset.
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): September 30, 2019 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-10 $ 101.4 $ (70.4 ) $ 31.0 Know how 1-6 186.0 (158.9 ) 27.1 Developed product technology 1-13 141.5 (90.1 ) 51.4 Licenses 6-10 75.7 (43.3 ) 32.4 Tradenames 2-10 6.4 (3.5 ) 2.9 Covenants not to compete 6 3.2 (1.3 ) 1.9 Other 1 0.1 — 0.1 Total definite-lived intangible assets 514.3 (367.5 ) 146.8 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 514.5 $ (367.5 ) $ 147.0 December 31, 2018 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-6 $ 88.7 $ (68.3 ) $ 20.4 Know how 1-7 190.6 (159.8 ) 30.8 Developed product technology 1-10 130.4 (86.6 ) 43.8 Licenses 7-11 76.3 (40.9 ) 35.4 Tradenames 2-6 3.9 (3.3 ) 0.6 Covenants not to compete 7 3.2 (1.1 ) 2.1 Total definite-lived intangible assets $ 493.1 $ (360.0 ) $ 133.1
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Amortization expense $ 6.0 $ 7.0 $ 17.1 $ 21.8

5. Supplemental Cash Flow In_2

5. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)	9 Months Ended
	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2019 September 30, 2018 Net income $ 1,205.2 $ 1,194.1 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 99.8 103.6 Right-of-use asset amortization 31.1 — Share-based compensation 25.4 19.2 (Gains) losses on dispositions of securities (0.2 ) 1.0 Other-than-temporary impairment loss on investment 1.6 — Change in fair market value of equity securities (1,385.0 ) (1,420.3 ) Gain on divestiture of a product line — (5.1 ) Losses on dispositions of fixed assets 0.3 1.2 Gain on sale of land — (4.1 ) Changes in fair value of contingent consideration (0.6 ) (6.5 ) Payments for operating lease liabilities (27.6 ) — Decrease in accounts receivable 30.4 72.2 Increase in inventories (14.5 ) (26.3 ) Decrease (increase) in other current assets 47.9 (8.9 ) Decrease in accounts payable and other current liabilities (24.6 ) (43.1 ) Decrease in income taxes payable (2.8 ) (22.1 ) Increase in deferred income taxes 310.9 316.7 Increase in other long term liabilities 5.5 5.4 Other (4.7 ) 3.5 Net cash provided by operating activities $ 298.1 $ 180.5 Non-cash investing activities: Purchased property, plant and equipment $ 4.5 $ 5.7 Purchased marketable securities and investments $ 2.8 $ 1.2
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2019 September 30, 2018 Net income $ 1,205.2 $ 1,194.1 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 99.8 103.6 Right-of-use asset amortization 31.1 — Share-based compensation 25.4 19.2 (Gains) losses on dispositions of securities (0.2 ) 1.0 Other-than-temporary impairment loss on investment 1.6 — Change in fair market value of equity securities (1,385.0 ) (1,420.3 ) Gain on divestiture of a product line — (5.1 ) Losses on dispositions of fixed assets 0.3 1.2 Gain on sale of land — (4.1 ) Changes in fair value of contingent consideration (0.6 ) (6.5 ) Payments for operating lease liabilities (27.6 ) — Decrease in accounts receivable 30.4 72.2 Increase in inventories (14.5 ) (26.3 ) Decrease (increase) in other current assets 47.9 (8.9 ) Decrease in accounts payable and other current liabilities (24.6 ) (43.1 ) Decrease in income taxes payable (2.8 ) (22.1 ) Increase in deferred income taxes 310.9 316.7 Increase in other long term liabilities 5.5 5.4 Other (4.7 ) 3.5 Net cash provided by operating activities $ 298.1 $ 180.5 Non-cash investing activities: Purchased property, plant and equipment $ 4.5 $ 5.7 Purchased marketable securities and investments $ 2.8 $ 1.2

6. Long-Term Debt (Tables)

6. Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): September 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.8 ) (1.3 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.2 423.7 Capital leases and other debt — 15.7 Finance leases and other debt 15.4 — 439.6 439.4 Less current maturities (1.8 ) (0.5 ) Long-term debt $ 437.8 $ 438.9

7. Accumulated Other Compreh_2

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (109.9 ) 0.1 5.1 (104.7 ) Amounts reclassified from Accumulated other comprehensive income — 0.6 (0.3 ) 0.3 Income tax effects — (0.2 ) (0.6 ) (0.8 ) Other comprehensive (loss) income, net of income taxes (109.9 ) 0.5 4.2 (105.2 ) Balances as of September 30, 2019: $ (145.4 ) $ (14.3 ) $ 7.5 $ (152.2 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2018: $ 77.4 $ (22.3 ) $ 4.5 $ 59.6 Other comprehensive (loss) income, before reclassifications (91.2 ) 0.5 (2.3 ) (93.0 ) Amounts reclassified from Accumulated other comprehensive income — 1.2 0.3 1.5 Income tax effects — (0.4 ) — (0.4 ) Other comprehensive (loss) income, net of income taxes (91.2 ) 1.3 (2.0 ) (91.9 ) Balances as of September 30, 2018: $ (13.8 ) $ (21.0 ) $ 2.5 $ (32.3 )
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended Nine Months Ended September 30, September 30, Components of Comprehensive income 2019 2018 2019 2018 Location Amortization of foreign other post-employment benefit items $ (0.2 ) $ (0.4 ) $ (0.6 ) $ (1.2 ) Other (income) expense, net Net holding gains (losses) on equity securities and available-for-sale investments $ 0.2 $ (0.1 ) $ 0.3 $ (0.3 ) Other (income) expense, net Reclassification adjustments are calculated using the specific identification method.

8. Earnings Per Share (Tables)

8. Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Basic weighted average shares outstanding 29,831 29,863 29,815 29,822 Effect of potentially dilutive stock options and restricted stock awards — 429 334 412 Diluted weighted average common shares 29,831 30,292 30,149 30,234 Anti-dilutive shares 95 64 56 35

9. Other Income and Expenses (

9. Other Income and Expenses (Tables)	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Interest and investment income $ (4.1 ) $ (2.6 ) $ (27.4 ) $ (20.9 ) Net realized (gain) loss on investments (0.2 ) 0.1 (0.2 ) 0.3 Other-than-temporary impairment loss on investment — — 1.6 — Gain on sale of land — — — (4.1 ) Gain on divestiture of product line — — — (5.1 ) Other (income) expense (0.1 ) (0.1 ) (1.0 ) 0.2 Other (income) expense, net $ (4.4 ) $ (2.6 ) $ (27.0 ) $ (29.6 )

11. Segment Information Segm_2

11. Segment Information Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding industry segments for the three months ended September 30, 2019 and 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 215.7 $ 341.8 $ 3.1 2018 $ 206.6 $ 334.0 $ 4.5 Segment net profit (loss) 2019 $ 11.6 $ 43.8 $ (0.4 ) 2018 $ 10.2 $ 22.4 $ 0.1 Information regarding industry segments for the nine months ended September 30, 2019 and 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 643.9 $ 1,032.9 $ 10.4 2018 $ 622.2 $ 1,038.8 $ 11.6 Segment net profit (loss) 2019 $ 45.9 $ 117.1 $ (1.1 ) 2018 $ 25.7 $ 86.8 $ 0.1 Information regarding industry segments at September 30, 2019 , and December 31, 2018 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment assets September 30, 2019 $ 500.0 $ 1,085.6 $ 7.8 December 31, 2018 $ 450.2 $ 949.0 $ 5.9
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	The following reconciles total segment profit to consolidated (loss) income before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Total segment profit $ 55.0 $ 32.7 $ 161.9 $ 112.6 Foreign currency exchange losses, net (0.9 ) (0.7 ) (3.4 ) (1.9 ) Net corporate operating, interest and other expense not allocated to segments (3.1 ) (2.5 ) (8.8 ) (6.7 ) Change in fair market value of equity securities (390.6 ) 318.0 1,385.0 1,420.3 Other income (expense), net 4.4 2.6 27.0 29.6 Consolidated (loss) income before income taxes $ (335.2 ) $ 350.1 $ 1,561.7 $ 1,553.9
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	The following reconciles total segment assets to consolidated total assets (in millions): September 30, 2019 December 31, 2018 Total segment assets $ 1,593.4 $ 1,405.1 Cash and other current assets 1,103.6 1,047.2 Property, plant and equipment, net, excluding segment specific gross machinery and equipment 64.0 79.9 Goodwill, net 264.1 219.8 Other long-term assets 4,152.0 2,859.1 Total assets $ 7,177.1 $ 5,611.1

13. Restructuring Costs (Tables

13. Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2018: $ 11.5 Adjustment to expense (0.3 ) Cash payments (7.4 ) Foreign currency translation gains (0.3 ) Balances as of September 30, 2019: $ 3.5

14. Leases (Tables)

14. Leases (Tables)	9 Months Ended
	Sep. 30, 2019
14. Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2019 Operating lease cost $ 14.2 $ 38.7 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.5 Interest on lease liabilities 0.2 0.7 Total finance lease cost $ 0.3 $ 1.2 Sublease income $ 0.7 $ 2.2 The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2019 (excluding the nine months ended September 30, 2019) $ 11.1 $ 1.2 2020 41.0 1.3 2021 35.4 1.2 2022 27.9 1.1 2023 24.3 1.1 Thereafter 141.3 15.4 Total lease payments 281.0 21.3 Less imputed interest (54.7 ) (9.6 ) Total $ 226.3 $ 11.7
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2019 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.6 $ 34.5 Operating cash flows from finance leases $ 0.2 $ 0.7 Financing cash flows from finance leases $ 0.1 $ 0.5 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 14.4 $ 20.2 Finance leases $ 0.1 $ 0.1
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2019 Operating Leases Operating lease right-of-use assets $ 217.5 Current operating lease liabilities $ 33.7 Operating lease liabilities 192.6 Total operating lease liabilities $ 226.3 September 30, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 Less: accumulated depreciation and amortization (4.0 ) Property, plant and equipment, net $ 7.4 Current maturities of long-term debt and notes payable $ 0.5 Long-term debt, net of current maturities 11.2 Total finance lease liabilities $ 11.7 September 30, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 Finance leases - in years 18 Weighted Average Discount Rate Operating leases 4.3 % Finance leases 6.5 %

1. Basis of Presentation and_3

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 560,633	$ 545,138	$ 1,687,231	$ 1,672,568
Cost of goods sold	253,607	258,422	760,674	781,982
Deferred Revenue	45,600		45,600				$ 37,300
Deferred Revenue, Period Increase (Decrease)			30,100
Revenue, Net			21,800
Retained earnings	4,917,313		4,917,313				3,722,073
Accumulated other comprehensive loss	(152,113)		(152,113)				(46,958)
Total stockholders' equity	$ 5,131,192	$ 4,900,481	$ 5,131,192	$ 4,900,481	$ 5,486,810	$ 4,863,855	4,020,331	$ 4,638,946	$ 4,488,091		$ 2,930,250
Revenue Allocation Percent To Lease Elements	3.00%	5.00%	3.00%	5.00%
Additional paid-in-capital	$ 396,432		$ 396,432				$ 394,342
Selling, general and administrative expense	201,622	$ 201,196	610,460	$ 620,751
Research and Development Expense	47,944	49,245	145,641	146,122
Interest expense	5,525	6,064	17,352	17,823
Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings										$ 100
Adjustments for New Accounting Pronouncement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capitalized Cloud Computing Arrangements	2,400		2,400
Europe [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	181,900	182,700	556,100	579,500
Asia Pacific [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	120,700	110,300	354,300	341,700
UNITED STATES
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	225,800	218,300	674,000	649,800
Americas [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 32,200	$ 33,800	$ 102,800	$ 101,600

1. Basis of Presentation and_4

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Accounting Policies [Abstract]
Warranty accrual, beginning of period	$ 10.1
Provision for warranty	7.3
Actual warranty costs	(8.4)
Warranty accrual, end of period	$ 9

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Aug. 02, 2019	Mar. 04, 2019
Business Combinations [Abstract]
Business Combination, Consideration Transferred	$ 60	$ 20
Payments to Acquire Businesses, Net of Cash Acquired	59.7	16	$ 4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 26.8	$ 5.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					$ 4.2
Goodwill, Acquired During Period	$ 28.7	15.6		$ 44.3
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						$ 0.2
Business Combination, Consideration Transferred, Liabilities Incurred		$ 1.3

3. Fair Value Measurements Fai

3. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 1,385
Debt Securities, Available-for-sale		370.9
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	$ 5.6
Equity Securities	[1]	3,950.5	2,672.9
Debt Securities, Available-for-sale	[2]	370.9	373.2
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0.5	0.6
Assets, Fair Value Disclosure		4,503.9	3,200
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0.8	0.7
Business Combination, Contingent Consideration, Liability	[5]	5.3	8.4
Liabilities, Fair Value Disclosure		6.1	9.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	5.6
Equity Securities	[1]	3,950.5	2,672.9
Debt Securities, Available-for-sale	[2]	0	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0	0
Assets, Fair Value Disclosure		4,042.6	2,738.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0	0
Business Combination, Contingent Consideration, Liability	[5]	0	0
Liabilities, Fair Value Disclosure		0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Equity Securities	[1]	0	0
Debt Securities, Available-for-sale	[2]	370.9	373.2
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0.5	0.6
Assets, Fair Value Disclosure		461.3	461.9
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0.8	0.7
Business Combination, Contingent Consideration, Liability	[5]	0	0
Liabilities, Fair Value Disclosure		0.8	0.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Equity Securities	[1]	0	0
Debt Securities, Available-for-sale	[2]	0	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0	0
Assets, Fair Value Disclosure		0	0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0	0
Business Combination, Contingent Consideration, Liability	[5]	5.3	8.4
Liabilities, Fair Value Disclosure		5.3	8.4
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	3.2
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	3.2
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0.1	0.3
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0.1	0.3
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Commercial Paper [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	76.6	77.8
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	76.6	77.8
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Time Deposits [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	33.6	32.7
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	23.6	22.7
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	10	10
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Money Market Funds [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	62.9	36.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	62.9	36.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	176.4	147.7
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	86.5	59.6
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	89.9	88.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	3.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	3.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0
Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	10.7	11
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	10.7	11
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	4.7	3.6
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	4.7	3.6
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	181.7	215
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	181.7	215
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	98.5	80.3
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	98.5	80.3
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	72.2	63.3
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	72.2	63.3
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[5]	3.7	3.2
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[5]	1.6	5.2
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[1]	47.4	40.2
Debt Securities, Available-for-sale	[2]	370.8	373
Short-term Investments [Member] | Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		3.1
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		10.7	11
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4.7	3.6
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		181.7	215
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		98.5	80.3
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		72.1	63.1
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[1]	3,903.1	2,632.7
Debt Securities, Available-for-sale	[2]	0.1	$ 0.2
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		5.3
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
[1]	Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 47.4 $ 40.2 Other investments 3,903.1 2,632.7 Total $ 3,950.5 $ 2,672.9
[2]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 370.8 $ 373.0 Other investments 0.1 0.2 Total $ 370.9 $ 373.2
[3]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[4]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[5]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Other current liabilities $ 3.7 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 5.3 $ 8.4
[6]	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

3. Fair Value Measurements 3.

3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended	28 Months Ended
		Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 5.3		$ 5.3		$ 8.4
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(1.1)	$ (1.4)	(2.5)
Business Combination, Contingent Consideration, Liability		$ 5.3		5.3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances				$ (0.6)	$ (12.9)
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%		39.00%
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate				11.40%
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate				3.90%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%		20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0		$ 0
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	5.3		5.3		8.4
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	1.6		1.6		5.2
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	$ 3.7		$ 3.7		$ 3.2
[1]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Other current liabilities $ 3.7 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 5.3 $ 8.4

3. Foreign Exchange Forward Co

3. Foreign Exchange Forward Contracts (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 37.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	232.5
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ (0.2)

3. Available-for-Sale Investme

3. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		$ 368.4
Debt Securities, Available-for-sale		370.9
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	370.9	$ 373.2
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	181.7	215
Fair Value, Recurring [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	10.7	11
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	98.5	80.3
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	4.7	3.6
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	3.1
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	72.2	63.3
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		368.4	375.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.8	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.3)	(2.6)
Debt Securities, Available-for-sale		370.9	373.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale		0.1	0.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale		0.1	0.2
Fair Value, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	370.8	373
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		180.3	216.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		1.5	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)	(1.3)
Debt Securities, Available-for-sale		181.7	215
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		10.6	11.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	(0.1)
Debt Securities, Available-for-sale		10.7	11
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		97.6	80.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		1	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)	(0.8)
Debt Securities, Available-for-sale		98.5	80.3
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		4.7	3.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale		4.7	3.6
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		3.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0
Debt Securities, Available-for-sale		3.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		72	63.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.2	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)	(0.4)
Debt Securities, Available-for-sale		72.1	63.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		368.3	375.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.8	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.3)	(2.6)
Debt Securities, Available-for-sale		370.8	373
Fair Value, Recurring [Member] | Other Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	$ 0.1	$ 0.2
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): September 30, 2019 December 31, 2018 Short-term investments $ 370.8 $ 373.0 Other investments 0.1 0.2 Total $ 370.9 $ 373.2

3. Amortized Cost and Fair Val

3. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Sep. 30, 2019USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 139.9
Mature in one to five years	168.3
Mature in more than five years	60.2
Total Amortized Cost	368.4
Mature in less than one year	140
Mature in one to five years	169.4
Mature in more than five years	61.5
Estimated Fair Value	$ 370.9

3. Fair Value and Gross Unreal

3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Price Change Debt Security	5.00%
Tolerable variance Level 2 debt security pricing	1.00%
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	$ 27.3	$ 117.9
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	90.3	193
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.1	1.8
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0.2	$ 0.8

3. Fair Value Financial Instru

3. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 3.6	$ 0.6
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	424.2	423.7
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	$ 435.1	$ 435.8

4. Intangible Assets, Goodwi_3

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2019	Mar. 04, 2019	Dec. 31, 2018
Goodwill [Line Items]
Goodwill	$ 599,300		$ 599,300		$ 555,000
Accumulated impairment loss	(335,200)		(335,200)		(335,200)
Goodwill, net	264,084		264,084		219,770
Goodwill, Acquired During Period	28,700	$ 15,600	44,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				$ 200
Life Science [Member]
Goodwill [Line Items]
Goodwill	250,100		250,100		234,500
Accumulated impairment loss	(41,800)		(41,800)		(41,800)
Goodwill, net	208,300		208,300		192,700
Goodwill, Acquired During Period			15,600
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	349,200		349,200		320,500
Accumulated impairment loss	(293,400)		(293,400)		(293,400)
Goodwill, net	$ 55,800		55,800		$ 27,100
Goodwill, Acquired During Period			$ 28,700

4. Intangible Assets, Goodwi_4

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Aug. 02, 2019	Mar. 04, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill, Acquired During Period	$ 28.7	$ 15.6		$ 44.3
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	514.3			514.3		$ 493.1
Accumulated Amortization	(367.5)			(367.5)		(360)
Net Carrying Amount	146.8			146.8		133.1
Amortization [Abstract]
Amortization expense	6		$ 7	17.1	$ 21.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 26.8	$ 5.5
Intangible Assets, Gross (Excluding Goodwill)	514.5			514.5
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	101.4			101.4		88.7
Accumulated Amortization	(70.4)			(70.4)		(68.3)
Net Carrying Amount	31			31		20.4
Amortization [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							16.1
Know How [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	186			186		190.6
Accumulated Amortization	(158.9)			(158.9)		(159.8)
Net Carrying Amount	27.1			27.1		30.8
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	141.5			141.5		130.4
Accumulated Amortization	(90.1)			(90.1)		(86.6)
Net Carrying Amount	51.4			51.4		43.8
Amortization [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							8.1
Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	75.7			75.7		76.3
Accumulated Amortization	(43.3)			(43.3)		(40.9)
Net Carrying Amount	32.4			32.4		35.4
Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	6.4			6.4		3.9
Accumulated Amortization	(3.5)			(3.5)		(3.3)
Net Carrying Amount	2.9			2.9		0.6
Amortization [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							2.5
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	3.2			3.2		3.2
Accumulated Amortization	(1.3)			(1.3)		(1.1)
Net Carrying Amount	1.9			1.9		$ 2.1
Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	0.1			0.1
Accumulated Amortization	0			0
Net Carrying Amount	0.1			$ 0.1
Amortization [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 0.1
Minimum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				1 year		1 year
Minimum [Member] | Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				1 year		1 year
Minimum [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				1 year		1 year
Minimum [Member] | Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				6 years		7 years
Minimum [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				2 years		2 years
Minimum [Member] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				6 years		7 years
Minimum [Member] | Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				1 year		0 years
Maximum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				10 years		6 years
Maximum [Member] | Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				6 years		7 years
Maximum [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				13 years		10 years
Maximum [Member] | Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				10 years		11 years
Maximum [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				10 years		6 years
Maximum [Member] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				6 years		7 years
Maximum [Member] | Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				1 year		0 years
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 0.2			$ 0.2

5. Supplemental Cash Flow In_3

5. Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Net Income Attributable to Parent	$ (258,816)	$ 598,810	$ 865,195	$ 269,326	$ 268,043	$ 656,774	$ 1,205,189	$ 1,194,143
Depreciation and Amortization							99,800	103,600
Right-of-use asset amortization							31,100	0
Share-based Payment Arrangement, Noncash Expense							25,400	19,200
(Gain) Loss on Sale of Securities, Net							(200)	1,000
Other than Temporary Impairment Losses on Investments							1,600	0
Changes in fair market value of equity securities							(1,385,000)	(1,420,300)
Gain on divestiture of a product line	0			0			0	(5,100)
Loss on Disposition of Property Plant Equipment							300	1,200
Gain on sale of land	$ 0			$ 0			0	(4,100)
Changes in fair value of contingent consideration							(600)	(6,500)
Payments for operating lease liabilities							(27,600)	0
Decrease in accounts receivable							30,400	72,200
Increase in inventories							(14,500)	(26,300)
Decrease (increase) in other current assets							47,900	(8,900)
Decrease in accounts payable and other current liabilities							(24,600)	(43,100)
Decrease in income taxes payable							(2,800)	(22,100)
Increase in deferred income taxes							310,900	316,700
Increase in other long term liabilities							5,500	5,400
Other							(4,700)	3,500
Net cash provided by operating activities							298,095	180,485
Noncash or Part Noncash Acquisition, Fixed Assets Acquired							4,500	5,700
Noncash or Part Noncash Acquisition, Investments Acquired							$ 2,800	$ 1,200

6. Long-Term Debt (Details)

6. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2010
Debt Instrument [Line Items]
Debt, Long-term and Short-term, Combined Amount	$ 439,600
Debt and Lease Obligation		$ 439,400
Other Long-term Debt, Current	1,800	500
Long-term debt, net of current maturities	437,808	438,937
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000	425,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 800	1,300
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 424,200	423,700	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]
Debt Instrument [Line Items]
Long-term Debt and Lease Obligation, Including Current Maturities	0	15,700
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	15,400	$ 0
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	3.225%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 200

7. Accumulated Other Compreh_3

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			$ (46,958)
Total other comprehensive income (loss) net of tax	$ (102,540)	$ (13,589)	(105,155)	$ (91,836)
Ending balance, Accumulated other comprehensive income	(152,113)		(152,113)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(35,500)	77,400
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(109,900)	(91,200)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			0	0
Other Comprehensive Income (Loss), Tax			0	0
Total other comprehensive income (loss) net of tax			(109,900)	(91,200)
Ending balance, Accumulated other comprehensive income	(145,400)	(13,800)	(145,400)	(13,800)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(14,800)	(22,300)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			100	500
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			600	1,200
Other Comprehensive Income (Loss), Tax			(200)	(400)
Total other comprehensive income (loss) net of tax			500	1,300
Ending balance, Accumulated other comprehensive income	(14,300)	(21,000)	(14,300)	(21,000)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(200)	(400)	(600)	(1,200)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			3,300	4,500
Other Comprehensive Income (Loss), before Reclassifications, before Tax			5,100	(2,300)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			(300)	300
Other Comprehensive Income (Loss), Tax			(600)	0
Total other comprehensive income (loss) net of tax			4,200	(2,000)
Ending balance, Accumulated other comprehensive income	7,500	2,500	7,500	2,500
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(200)	100	(300)	300
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(47,000)	59,600
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(104,700)	(93,000)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			300	1,500
Other Comprehensive Income (Loss), Tax			(800)	(400)
Total other comprehensive income (loss) net of tax			(105,200)	(91,900)
Ending balance, Accumulated other comprehensive income	$ (152,200)	$ (32,300)	$ (152,200)	$ (32,300)

8. Earnings Per Share (Details

8. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Basic weighted average shares outstanding	29,831	29,863	29,815	29,822
Effect of potentially dilutive stock options and restricted stock awards	0	429	334	412
Diluted weighted average common shares	29,831	30,292	30,149	30,234
Anti-dilutive shares	95	64	56	35

9. Other Income and Expenses_2

9. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Interest and investment income	$ (4,100)	$ (2,600)	$ (27,400)	$ (20,900)
Net realized (gain) loss on investments	(200)	100	(200)	300
Other than Temporary Impairment Losses on Investment	0	0	1,600	0
Gain on sale of land	0	0	0	(4,100)
Gain on divestiture of a product line	0	0	0	(5,100)
Other Nonoperating Income	(100)	(100)	(1,000)
Other Nonoperating Expense				(200)
Nonoperating (Income( Expense	$ (4,367)	$ (2,585)	$ (26,959)	$ (29,588)

10. Income Taxes (Details)

10. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Effective tax rate	23.00%	23.00%	23.00%	23.00%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 2.1		$ 2.1

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Net sales	$ 560,633	$ 545,138	$ 1,687,231	$ 1,672,568
Income before income taxes	(335,216)	350,131	1,561,651	1,553,906
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	215,700	206,600	643,900	622,200
Income before income taxes	11,600	10,200	45,900	25,700
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	341,800	334,000	1,032,900	1,038,800
Income before income taxes	43,800	22,400	117,100	86,800
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	3,100	4,500	10,400	11,600
Income before income taxes	$ (400)	$ 100	$ (1,100)	$ 100

11. Segment Information Segm_3

11. Segment Information Segment Profit Reconciliations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ (335,216)	$ 350,131	$ 1,561,651	$ 1,553,906
Marketable Securities, Unrealized Gain (Loss)	(390,620)	318,007	1,384,999	1,420,339
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	55,000	32,700	161,900	112,600
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(3,100)	(2,500)	(8,800)	(6,700)
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	(390,600)	318,000	1,385,000	1,420,300
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(900)	(700)	(3,400)	(1,900)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 4,400	$ 2,600	$ 27,000	$ 29,600

11. Segment Information Segm_4

11. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 7,177,116	$ 5,611,068
Operating Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	1,593,400	1,405,100
Other Current Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	1,103,600	1,047,200
Property, Plant and Equipment excluding segment specific [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	64,000	79,900
Goodwill [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	264,100	219,800
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	4,152,000	2,859,100
Life Science [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	500,000	450,200
Clinical Diagnostics [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	1,085,600	949,000
Other Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 7,800	$ 5,900

12. Legal Proceedings 12. Cont

12. Legal Proceedings 12. Contingent Liability (Details) - USD ($)	Feb. 26, 2019	Dec. 31, 2018
Legal Proceedings [Abstract]
Loss Contingency, Damages Awarded, Value	$ 7,960,000	$ 10,920,000
Litigation Settlement Interest		$ 141,608
Loss Contingency Accrual, Period Increase (Decrease)	$ (2,960,000)

13. Restructuring Costs (Detail

13. Restructuring Costs (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	10 Months Ended	16 Months Ended	22 Months Ended	41 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
European Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges						$ 12.7
Restructuring Reserve, Accrual Adjustment	$ 0.1	$ (0.1)
European Reorganization [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		(0.1)
European Reorganization [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	0.7	0.7	$ 0.7	$ 0.7	$ 0.7	0.7
Termination of a Diagnostics Research and Development Project [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges					21.4
Restructuring Reserve, Accrual Adjustment	0.1	(0.1)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	3.5	3.5	3.5	3.5	3.5	3.5	$ 11.5
Restructuring Reserve, Accrual Adjustment		(0.3)
Payments for Restructuring		(7.4)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		(0.3)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0	(0.2)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0	(0.1)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	1.4	1.4	1.4	1.4	1.4	1.4
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	0.2	0.2	0.2	0.2	0.2	0.2
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	1.9	1.9	1.9	1.9	$ 1.9	$ 1.9
GERMANY | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				$ 1.4
Restructuring Reserve, Accrual Adjustment	0	(0.3)
FRANCE | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 4.1
Restructuring Reserve, Accrual Adjustment	$ 0	$ (0.1)

14. Leases (Details)

14. Leases (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 11,100	$ 11,100
Finance Lease, Liability, Payments, Remainder of Fiscal Year	$ 1,200	$ 1,200
Operating Lease, Weighted Average Remaining Lease Term	9 years	9 years
Finance Lease, Weighted Average Remaining Lease Term	18 years	18 years
Operating Lease, Weighted Average Discount Rate, Percent	4.30%	4.30%
Property, plant and equipment, gross	$ 1,347,364	$ 1,347,364	$ 1,326,829
Operating Leases, Future Minimum Payments Due, Next Twelve Months			44,400
Operating Leases, Future Minimum Payments, Due in Two Years			37,800
Operating Leases, Future Minimum Payments, Due in Three Years			27,400
Operating Leases, Future Minimum Payments, Due in Four Years			19,700
Operating Leases, Future Minimum Payments, Due in Five Years			13,900
Operating Leases, Future Minimum Payments, Due Thereafter			25,600
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals			17,800
Less: accumulated depreciation and amortization	(851,488)	(851,488)	(818,139)
Property, plant and equipment, net	495,876	495,876	508,690
Finance Lease, Liability, Current	500	500
Finance Lease, Liability, Noncurrent	11,200	11,200
Finance Lease, Liability	$ 11,700	$ 11,700
Finance Lease, Weighted Average Discount Rate, Percent	6.50%	6.50%
Lessee, Operating Lease, Liability, Payments, Due Year Two	$ 41,000	$ 41,000
Finance Lease, Liability, Payments, Due Year Two	1,300	1,300
Lessee, Operating Lease, Liability, Payments, Due Year Three	35,400	35,400
Finance Lease, Liability, Payments, Due Year Three	1,200	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Four	27,900	27,900
Finance Lease, Liability, Payments, Due Year Four	1,100	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Five	24,300	24,300
Finance Lease, Liability, Payments, Due Year Five	1,100	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	141,300	141,300
Finance Lease, Liability, Payments, Due after Year Five	15,400	15,400
Lessee, Operating Lease, Liability, Payments, Due	281,000	281,000
Finance Lease, Liability, Payment, Due	21,300	21,300
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(54,700)	(54,700)
Capital Leases, Future Minimum Payments Due, Next Twelve Months			500
Capital Leases, Future Minimum Payments Due in Two Years			200
Capital Leases, Future Minimum Payments Due in Three Years			500
Capital Leases, Future Minimum Payments Due in Four Years			400
Capital Leases, Future Minimum Payments Due in Five Years			400
Capital Leases, Future Minimum Payments Due Thereafter			9,900
Finance Lease, Liability, Undiscounted Excess Amount	(9,600)	(9,600)
Operating lease right-of-use assets	217,516	217,516	0
Operating Lease, Payments	11,600	34,500
Operating Lease, Cost	14,200	38,700
Finance Lease, Right-of-Use Asset, Amortization	100	500
Finance Lease, Interest Expense	200	700
Finance Lease Cost	300	1,200
Sublease Income	700	2,200
Finance Lease, Interest Payment on Liability	200	700
Finance Lease, Principal Payments	100	500
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	14,400	20,200
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	100	100
Current operating lease liabilities	33,694	33,694	0
Operating lease liabilities	192,600	192,600	$ 0
Operating Lease, Liability	226,300	$ 226,300
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term		1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term		20 years
Finance Lease [Member]
Lessee, Lease, Description [Line Items]
Property, plant and equipment, gross	11,400	$ 11,400
Less: accumulated depreciation and amortization	(4,000)	(4,000)
Property, plant and equipment, net	$ 7,400	$ 7,400

Uncategorized Items - a10q93019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 846,762,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1,526,019,000
AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (679,257,000)